Abstract 103P
Background
Texture analysis is used to assess the homogeneous or nonhomogenous information of the selected regions, and provides many quantitative and semiquantitative parameters that are able to closely reflect the characteristics of cancer lesions. This study was designed to estimate the clinical significance of the contrast-enhanced computed tomograpgy (CT) textural features for prediction of survival in colorectal cancer (CRC) patients receiving targeted therapy (bevacizumab and cetuximab).
Methods
The LifeX software was used to extract the textural parameters of the tumor lesions in the contrast-enhanced CT. Univariate and multivariate analyses using the Cox proportional hazards model were performed to assess the prognostic value of textural parameters.
Results
Eighty CRC patients receiving targeted therapy (bevacizumab 42; cetuximab 38) were included. In the multivariate analysis, 8 textural parameters were revealed to be independent predictors (p < 0.05) of progression-free survival (PFS) and overall survival (OS), including Skewness, Kurtosis, Homogeneity, Energy and Entropy of Gray-level co-occurrence matrix (GLCM), Long-run emphasis (LRE), Long-run high gray-level emphasis (LRHGE), and Contrast. Furthermore, Sphericity, Compacity, Long-run low gray-level emphasis (LRLGE), Low gray-level zone emphasis (LGZE) and Short-zone low gray-level emphasis (SZLGE) were show to be significantly associated with PFS, while Entropy-Histogram and Energy-Histogram, Dissimilarty, Short-run emphasis (SRE), Short-run low gray-level emphasis (SRLGE), Run percentage (RP), Long-zone emphasis (LZE), Long-zone low gray-level emphasis (LZLGE) and Long-zone high gray-level emphasis (LZHGE) were significantly associated with OS.
Conclusions
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract